Home > Press > Medtronic Makes Equity Investment in NanoCor Therapeutics, Inc.
NanoCor Therapeutics, Inc. (NanoCor) today announces an investment by Medtronic, Inc. of $3.75 million. NanoCor intends to use this investment to develop and commercialize a gene therapy based therapeutic for Congestive Heart Failure (CHF). Medtronic has also agreed to invest an additional $3.75 million upon NanoCor meeting certain milestones. NanoCor, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), was created to focus on therapeutic cardiac applications and is engaged in the development of proprietary treatments for CHF.
Medtronic Makes Equity Investment in NanoCor Therapeutics, Inc.
CHAPEL HILL, NC | Posted on September 10th, 2007
In connection with the investment, Medtronic acquires certain rights to exclusively license NanoCor's CHF therapeutic. NanoCor's therapeutic consists of the delivery of a proprietary gene developed at the Massachusetts General Hospital and the University of Cincinnati. The gene will be delivered with AskBio's proprietary Biological NanoParticle (BNP™) and Self-Complementary vector technologies, which are derived from human adeno-associated virus vectors (rAAV). This technology was developed at the University of North Carolina at Chapel Hill (UNC) and exclusively licensed to AskBio. In addition, Medtronic acquires certain rights to develop AskBio's BNP™ and Self-Complimentary technologies for the treatment of Central Nervous System (CNS) diseases.
About Congestive Heart Failure
CHF is a condition in which the heart is unable to supply sufficient amounts of blood and oxygen to the body. CHF can result from conditions that weaken the heart muscle, cause stiffening of the heart muscles, or increase oxygen demand by the body tissue beyond the heart's capability to deliver. Approximately five million patients in the US suffer from CHF.
About NanoCor Therapeutics, Inc.
NanoCor Therapeutics, Inc. ( http://www.nanocorthx.com ) is a privately held biotechnology company founded to treat CHF at the molecular level. Using the BNP™ and Self-Complementary technology platforms and a novel, patent-protected gene, NanoCor intends to provide patients currently suffering from CHF with an effective, safe, and non-invasive treatment. NanoCor Therapeutics, Inc. is a subsidiary of AskBio.
About Asklepios BioPharmaceutical, Inc.
AskBio (www.askbio.com) was spun out of UNC and is engaged in the development of novel, intracellular protein therapeutics using its BNPTM and Self-Complementary technologies. BNPsTM may be used to deliver a broad variety of biological material, including therapeutic genes, RNAi, and vaccines, among others, to specific tissues. The company is developing therapeutics for muscular dystrophy (collaborating with the Muscular Dystrophy Association), bone regrowth (collaborating with the Musculoskeletal Tissue Foundation), and hemophilia.
For more information, please click here
NanoCor Therapeutics, Inc.
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014
Aspen Aerogels, Inc. to Present at Barclays CEO Energy-Power Conference August 27th, 2014
Harris & Harris Group Letter to Shareholders on Website August 19th, 2014
Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 August 12th, 2014
Researchers Create World’s Largest DNA Origami September 11th, 2014
Iranian Scientists Discover Nanotechnology Method to Remove Limitations in Tumor Surgery September 11th, 2014
Iranian Nanotechnology Scientists Produce Polymeric Scaffolds for Tissue Engineering September 11th, 2014
Combining antibodies, iron nanoparticles and magnets steers stem cells to injured organs:Study published in Nature Communications details targeted nanomedicine therapy to regenerate heart muscle injured by heart attack September 11th, 2014
Seeking Nanoscale Defenses for Biological and Chemical Threats: WPI co-organizes a NATO workshop to improve the detection and decontamination of biological and chemical agents September 13th, 2014
New pricing report for bulk graphene materials September 13th, 2014
Berkeley Lab Licenses Boron Nitride Nanotube Technology: New material has unique mechanical and electronic properties September 13th, 2014
Iranian Nano Scientists Create Flame-Resistant Polymers September 13th, 2014